CIBRA Capital Ltd Acquires Shares of 210,800 Amicus Therapeutics, Inc. $FOLD

CIBRA Capital Ltd bought a new position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the 4th quarter, Holdings Channel.com reports. The fund bought 210,800 shares of the biopharmaceutical company’s stock, valued at approximately $3,002,000. Amicus Therapeutics makes up approximately 5.2% of CIBRA Capital Ltd’s holdings, making the stock its 11th biggest holding.

Several other institutional investors also recently bought and sold shares of FOLD. GAMMA Investing LLC increased its holdings in Amicus Therapeutics by 167.1% in the 4th quarter. GAMMA Investing LLC now owns 1,987 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 1,243 shares during the last quarter. Allworth Financial LP boosted its holdings in Amicus Therapeutics by 36.3% during the 3rd quarter. Allworth Financial LP now owns 4,678 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 1,246 shares during the period. Allianz Asset Management GmbH grew its position in Amicus Therapeutics by 0.3% in the 3rd quarter. Allianz Asset Management GmbH now owns 389,109 shares of the biopharmaceutical company’s stock valued at $3,066,000 after acquiring an additional 1,333 shares during the last quarter. Van ECK Associates Corp increased its stake in Amicus Therapeutics by 35.1% in the third quarter. Van ECK Associates Corp now owns 5,638 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 1,466 shares during the period. Finally, Parallel Advisors LLC lifted its position in shares of Amicus Therapeutics by 40.2% during the third quarter. Parallel Advisors LLC now owns 5,756 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 1,649 shares during the last quarter.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 75,000 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $14.31, for a total value of $1,073,250.00. Following the completion of the sale, the chief executive officer directly owned 1,021,180 shares in the company, valued at approximately $14,613,085.80. This trade represents a 6.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.20% of the stock is owned by corporate insiders.

Amicus Therapeutics Trading Down 0.1%

NASDAQ:FOLD opened at $14.41 on Friday. The stock has a market capitalization of $4.52 billion, a price-to-earnings ratio of -180.13 and a beta of 0.43. Amicus Therapeutics, Inc. has a 52 week low of $5.51 and a 52 week high of $14.43. The company has a quick ratio of 1.88, a current ratio of 2.84 and a debt-to-equity ratio of 1.43. The firm has a 50 day moving average of $14.34 and a 200 day moving average of $11.63.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.03). The firm had revenue of $185.21 million during the quarter, compared to analysts’ expectations of $185.00 million. Amicus Therapeutics had a positive return on equity of 4.15% and a negative net margin of 4.27%.Amicus Therapeutics’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.09 earnings per share. As a group, sell-side analysts anticipate that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on FOLD. TD Cowen lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 target price for the company. in a research note on Monday, December 22nd. Leerink Partners downgraded shares of Amicus Therapeutics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $17.00 to $14.50 in a research note on Monday, December 29th. Jefferies Financial Group reaffirmed a “hold” rating and set a $14.50 target price (down from $16.00) on shares of Amicus Therapeutics in a research report on Thursday, January 22nd. Guggenheim lowered Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 5th. Finally, Zacks Research cut Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 26th. Three equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $15.39.

Amicus Therapeutics Company Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.